HYPOLIPIDEMIC MEDICATIONS: CURRENT USE AND FUTURE PERSPECTIVES. PART 2. A COMMON APPROACHES FOR STATIN’S USING
This article is devoted to discussion about main aspects of current use of 3-hydroxy-3-methylglutaril CoA reductase inhibitors (statins) according last international guidelines. Statin’s base effects on lipid profile, medication regimens, side effects and safety ensuring are represented.
Main Authors: | A. E. Bagriy, A. I. Dyadyk, M. V. Khomenko, I. N. Tsiba, V. A. Efremenko, E. V. Schukina, O. A. Prikolota |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Siberian Branch of Russian Academy of Sciences, Research Institute of Internal and Preventive Medicine, branch of the Institute of Cytology and Genetics
2016-06-01
|
Series: | Атеросклероз |
Subjects: | |
Online Access: | https://ateroskleroz.elpub.ru/jour/article/view/17/17 |
Similar Items
-
HYPOLIPIDEMIC MEDICATIONS: CURRENT USE AND FUTURE PERSPECTIVES. PART 3. STATIN’S USING IN DIFFERENT PATIENT’S CATEGORY
by: A. E. Bagriy, et al.
Published: (2016-09-01) -
HYPOLIPIDEMIC MEDICATIONS: CURRENT USE AND FUTURE PERSPECTIVES. PART 1. NON-STATIN HYPOLIPIDEMIC MEDICATIONS
by: A. E. Bagriy, et al.
Published: (2016-03-01) -
Shared Decisions: A Qualitative Study on Clinician and Patient Perspectives on Statin Therapy and Statin‐Associated Side Effects
by: Sarah T. Ahmed, et al.
Published: (2020-11-01) -
ATORVASTATIN IN ACUTE AND CHRONIC KINDS OF ISCHEMIC HEART DISEASE
by: V. E. Oleynikov, et al.
Published: (2015-11-01) -
Statin-induced myopathy – a challenge for patients and physicians
by: Gabriela Anca ANGELESCU, et al.
Published: (2021-06-01)